Trial Profile
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- 11 Oct 2016 Results assessing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
- 01 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 29 Feb 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.